Advancing Retinal Disease Treatment – The Next Generation of Anti-VEGF Therapies

Ehsan Rahimy, MD; David G. Miller, MD; and Esther Kim, MD, discuss how achieving retinal drying through anti-VEGF therapies remains a critical marker of treatment success in retinal diseases such as age-related macular degeneration and diabetic macular edema while highlighting the benefits of newer agents such as aflibercept 8 mg and faricimab for providing better durability and sustained disease control with reduced treatment burden.